CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $6,461 | $549 | $10,055 | $5,005 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $883 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,315 | $1,042 | $2,509 | $2,473 |
| Total Curr. Assets | $8,659 | $1,591 | $12,565 | $7,477 |
| Property Plant & Equip (Net) | $6 | $5 | $6 | $16 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $36 | $105 | $483 | $1,264 |
| Total NC Assets | $42 | $110 | $488 | $1,280 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $8,701 | $1,701 | $13,053 | $8,757 |
| Liabilities | – | – | – | – |
| Payables | $2,198 | $5,832 | $3,682 | $1,523 |
| Short-Term Debt | $326 | $301 | $410 | $388 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $828 | $225 |
| Total Curr. Liab. | $2,524 | $6,133 | $4,920 | $2,136 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $2,524 | $6,133 | $4,920 | $2,136 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1 | $6 | $2 | $28 |
| Retained Earnings | -$84,425 | -$69,567 | -$50,716 | -$34,983 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $90,600 | $65,129 | $58,847 | $41,577 |
| Total Equity | $6,177 | -$4,432 | $8,133 | $6,622 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $8,701 | $1,701 | $13,053 | $8,757 |
| Net Debt | -$6,135 | -$248 | -$9,645 | -$4,617 |